Publication | Open Access
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
3.2K
Citations
26
References
2019
Year
Merck Sharp & Dohme.
| Year | Citations | |
|---|---|---|
Page 1
Page 1